DAS β (95% CI) | DAS28 β (95% CI) | HAQ β (95% CI) | |
---|---|---|---|
Methotrexate monotherapy (number of patients = 522, number of visits = 1090) | |||
MTX dose group PS-adjusted | 0.070 (−0.15; 0.29) | 0.12 (−0.19; 0.43) | 0.060 (−0.09; 0.21 |
MTX dose group unadjusted | −0.63 (−0.79; −0.47) | −0.90 (−0.13; −0.67) | 0.16 (0.055; 0.26) |
Methotrexate + csDMARDs (number of patients = 262, number of visits = 567) | |||
MTX dose group PS-adjusted | 0.051 (−0.23; 0.33) | 0.024 (−0.37; 0.42) | −0.0058 (−0.20; 0.19) |
MTX dose group unadjusted | −0.18 (−0.44; 0.072) | −0.28 (−0.63; 0.072) | 0.092 (−0.085; 0.27) |
Methotrexate + oral glucocorticoid (+/−csDMARDs) (number of patients = 615, number of visits = 1403) | |||
MTX dose group PS-adjusted | −0.047 (−0.26; 0.16) | −0.16 (−0.44; 0.12) | −0.028 (−0.16; 0.11) |
MTX dose group unadjusted | −0.42 (−0.56; 0.28) | −0.74 (−0.93; −0.55) | 0.13 (0.045; 0.22) |